The new anti-tumor drug introduced by Lee's Big Pharma has been approved for marketing

Today (April 21), the official website of the China National Medical Products Administration (NMPA) announced that the new anti-tumor drug Procarbazine Hydrochloride Capsules (Natulan) submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved

Screenshot source: NMPA official website

Procarbazine Hydrochloride Capsule is an alkylating agent drug and a cycle non-specific antineoplastic drug, which is clinically suitable for the treatment of advanced Hodgkin lymphoma and some brain cancers (such as glioblastoma multiforme)

According to public information, procarbazine hydrochloride capsules were originally developed by Roche and have been approved for marketing overseas, and are produced by Leadiant Biosciences (formerly Sigma-Tau)

In May 2020, Lee's Big Pharma issued a press release saying that the new drug marketing application for procarbazine hydrochloride capsules has been accepted by the NMPA

The results showed that a total of 93 patients with advanced Hodgkin lymphoma participated in the study, and the results of the study not only matched its main final goal, that is, the objective response rate of the BEACOPP baseline regimen group was not inferior to the ABVD regimen group

Hodgkin lymphoma is a relatively rare B-cell malignant lymphoma, which mostly occurs in young people aged 20 to 40 years.

references:

[1] On April 21, 2022, the release of the drug approval document pending collection.

[3]Liu Zhijun,Chen Heru.